GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » Cyclically Adjusted PS Ratio

Exact Sciences (STU:EXK) Cyclically Adjusted PS Ratio : 6.08 (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences Cyclically Adjusted PS Ratio?

As of today (2024-06-09), Exact Sciences's current share price is €40.64. Exact Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €6.68. Exact Sciences's Cyclically Adjusted PS Ratio for today is 6.08.

The historical rank and industry rank for Exact Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:EXK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 5.72   Med: 70.96   Max: 273
Current: 5.72

During the past years, Exact Sciences's highest Cyclically Adjusted PS Ratio was 273.00. The lowest was 5.72. And the median was 70.96.

STU:EXK's Cyclically Adjusted PS Ratio is ranked worse than
76.34% of 131 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.5 vs STU:EXK: 5.72

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Exact Sciences's adjusted revenue per share data for the three months ended in Mar. 2024 was €3.216. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €6.68 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Exact Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Exact Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Cyclically Adjusted PS Ratio Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.62 51.03 20.07 9.21 10.56

Exact Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.66 15.04 10.25 10.56 9.21

Competitive Comparison of Exact Sciences's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Exact Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Cyclically Adjusted PS Ratio falls into.



Exact Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Exact Sciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=40.64/6.68
=6.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exact Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Exact Sciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.216/131.7762*131.7762
=3.216

Current CPI (Mar. 2024) = 131.7762.

Exact Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.014 99.070 0.019
201503 0.044 99.621 0.058
201506 0.081 100.684 0.106
201509 0.119 100.392 0.156
201512 0.137 99.792 0.181
201603 0.137 100.470 0.180
201606 0.193 101.688 0.250
201609 0.239 101.861 0.309
201612 0.306 101.863 0.396
201703 0.409 102.862 0.524
201706 0.455 103.349 0.580
201709 0.511 104.136 0.647
201712 0.615 104.011 0.779
201803 0.605 105.290 0.757
201806 0.721 106.317 0.894
201809 0.826 106.507 1.022
201812 1.022 105.998 1.271
201903 1.136 107.251 1.396
201906 1.369 108.070 1.669
201909 1.533 108.329 1.865
201912 1.900 108.420 2.309
202003 2.125 108.902 2.571
202006 1.595 108.767 1.932
202009 2.309 109.815 2.771
202012 2.449 109.897 2.937
202103 1.993 111.754 2.350
202106 2.104 114.631 2.419
202109 2.256 115.734 2.569
202112 2.431 117.630 2.723
202203 2.533 121.301 2.752
202206 2.798 125.017 2.949
202209 2.985 125.227 3.141
202212 2.939 125.222 3.093
202303 3.151 127.348 3.261
202306 3.186 128.729 3.261
202309 3.198 129.860 3.245
202312 3.275 129.419 3.335
202403 3.216 131.776 3.216

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exact Sciences  (STU:EXK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Exact Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences (STU:EXK) Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.